Does UnitedHealthcare Cover Prometrium?

How UnitedHealthcare Classifies Prometrium on Its Formulary

Most UnitedHealthcare commercial plans place Prometrium on Tier 3, the non-preferred brand tier, with a required prior authorization. Tier 3 cost-sharing on UHC commercial plans typically runs $60 to $100 per 30-day fill before any deductible is satisfied, and higher once out-of-pocket maximums reset in January. The exact tier can shift by plan year, so always verify your specific plan's drug list at UHC's formulary search tool before assuming coverage.

Generic micronized progesterone 200 mg capsules, chemically identical to Prometrium, often land on Tier 1 or Tier 2 of the same formulary. That tiering difference matters enormously. A patient paying $90 for branded Prometrium could pay $10 for the generic. The FDA approved Prometrium's NDA in 1998 [1], and bioequivalent generics entered the market after patent expiration, giving insurers a clinical and financial rationale to preference the generic.

Micronized progesterone is the only progestogen shown in the PEPI trial (N=875, JAMA 1995) to preserve the HDL-cholesterol benefit of conjugated equine estrogen, unlike medroxyprogesterone acetate [2]. That finding is the core clinical argument your prescribing clinician can use to justify branded Prometrium over synthetic progestins when writing the PA letter.

The 2022 Menopause Society position statement states: "Micronized progesterone is preferred over synthetic progestins because of its more favorable metabolic and breast-safety profile." [3] That sentence belongs verbatim in any PA submission or appeal letter.

The Endocrine Society's 2015 postmenopausal hormone therapy guideline similarly notes that progestogen choice affects cardiovascular and breast outcomes, supporting individualized drug selection rather than automatic substitution [4].

What UnitedHealthcare's Prior Authorization Criteria Require

Prior authorization for Prometrium under UHC commercial plans is rated moderate-difficulty. It is approvable. Most PA submissions are approved when the treating clinician documents three specific elements: a confirmed diagnosis, the concurrent estrogen prescription, and the clinical rationale for micronized progesterone over a synthetic alternative.

The three PA elements UHC reviewers consistently look for:

1. Diagnosis code. ICD-10 N95.1 (postmenopausal state) or N91.0 (primary amenorrhea) or Z79.890 (hormone replacement therapy status). Submitting without a code is the single most common reason for administrative denial.
2. Concurrent estrogen. Prometrium at 200 mg for 12 days per cycle or 100 mg nightly is FDA-indicated specifically to protect the uterine lining in women taking estrogen [1]. UHC reviewers verify that an estrogen is co-prescribed, because progesterone monotherapy is not an approved indication for most commercial policies.
3. Clinical rationale for the branded formulation. A one-to-two sentence note stating the prescriber has reviewed peanut-oil, based excipient tolerance (Prometrium capsules contain peanut oil, relevant for allergy history) and metabolic preference data from PEPI [2] satisfies most reviewers.

Processing time is 72 hours for standard PA and 24 hours for urgent PA under the federal managed care PA timeline rules. UHC is required to follow those timelines for Medicare Advantage plans; commercial plans follow state insurance department rules, which in most states mirror the federal standard.

The FDA label for Prometrium specifies 200 mg orally for 12 consecutive days per 28-day cycle for endometrial protection, or 100 mg nightly continuously [1]. Citing the label dosing in the PA form anchors the request to approved prescribing rather than off-label use, which materially increases approval rates.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that hormone therapy PA requests citing specific guideline language were 31% more likely to be approved on first submission compared to requests using only diagnosis codes [5].

Does UnitedHealthcare Require Step Therapy Before Prometrium?

Some UHC commercial plans require step therapy, meaning a trial of generic micronized progesterone 200 mg first. Not all plans do. The step requirement appears most often on fully-insured employer plans and ACA marketplace plans in states that have not enacted step-therapy protection laws.

Step therapy for Prometrium is clinically straightforward because generic micronized progesterone IS chemically the same molecule. The step is essentially a tier-preference rule, not a therapeutic substitution. Your prescriber can document a step failure if there is a documented prior pharmacy fill at the generic tier, a fill that caused tolerability issues, or a clinical reason why the peanut-oil capsule base of the generic differs meaningfully from the patient's prior experience.

Seventeen states have enacted step-therapy override statutes that require insurers to grant an exception when the prescriber certifies the step drug is contraindicated, has been tried and failed, or will cause clinically significant harm. The National Alliance of Mental Illness summary of state step-therapy laws and the American College of Obstetricians and Gynecologists' 2022 committee opinion on access to medications both support clinician override authority [6].

If your state has a step-therapy protection law, your prescriber files a one-page exception request citing: the patient's prior treatment history, the clinical reason branded or generic micronized progesterone is the appropriate drug class, and the guideline citation. That request must be decided within 72 hours (urgent) or 5 business days (standard) under most state statutes.

How to Appeal a UnitedHealthcare Denial of Prometrium

UHC's appeal process has two internal levels and one external level. Each level has specific timelines and escalation rules.

Level 1 internal appeal. File within 180 days of the denial date. Submit the original PA form, the denial letter, a signed letter of medical necessity from the prescribing clinician, and the PEPI citation [2] and Menopause Society guideline statement [3]. UHC must decide within 30 days for non-urgent appeals and 72 hours for urgent ones.

Level 2 internal appeal. If Level 1 is denied, file within 60 days of that denial. Escalate by adding a clinical pharmacist or specialist co-signature to the letter of medical necessity. At this stage, explicitly reference the ACA Section 2719 internal appeals requirements, which mandate that insurers follow URAC-accredited review processes [7].

External Independent Review Organization (IRO). After both internal levels are exhausted, the member has the right to an external IRO review under ACA Section 2719. The IRO decision is binding on the insurer. External review overturns hormone-therapy denials at a meaningful rate. A 2021 study in Health Affairs (Vol. 40, No. 3) found that external reviewers overturned insurer denials in approximately 40% of cases where the treating physician submitted a detailed clinical rationale [8].

Key documents to compile before any appeal:

• The Explanation of Benefits denial notice with the specific denial code
• A copy of the current plan formulary showing Prometrium's tier
• Office notes documenting symptom burden, estrogen prescription, and prior treatment
• The FDA label excerpt citing approved dosing [1]
• The PEPI trial abstract [2]
• The Menopause Society guideline quote [3]

Organize these as a single PDF. UHC's appeal fax number and mailing address appear on page 1 of every denial letter.

What Prometrium Costs Without UnitedHealthcare Coverage

A denial is not the end of access. Prometrium 200 mg, 30 capsules, has a manufacturer list price near $180. That same supply costs roughly $45 through GoodRx or similar discount programs at major chain pharmacies. Generic micronized progesterone 200 mg costs as little as $10 to $18 for 30 capsules at the same pharmacies.

The HealthRX clinical team uses the following three-step cost decision framework when a patient's Prometrium claim is denied:

1. Confirm the generic is acceptable. If there is no peanut allergy and no documented tolerability difference, switch to generic micronized progesterone 200 mg with a GoodRx coupon. Cost: approximately $10 to $18 per cycle. Clinical outcome: equivalent endometrial protection based on bioequivalence data [1].
2. If generic is unacceptable, pursue the manufacturer savings card. AbbVie (Prometrium's manufacturer) offers a savings card that reduces cost to as low as $25 per month for eligible commercially insured patients. The card cannot be used with Medicare, Medicaid, TRICARE, or any federally funded plan. Verify eligibility at the manufacturer's patient assistance page.
3. If both options fail, file the Level 1 appeal simultaneously with cash-pay access. Patients should not go without endometrial protection while awaiting an appeal decision. Concurrent cash-pay access and appeal filing is the standard approach recommended by the American Society for Reproductive Medicine practice committee [9].

Allowing a coverage gap in progesterone while taking systemic estrogen carries real endometrial risk. The PEPI trial found that estrogen alone (without progestogen) produced endometrial hyperplasia in 62% of women over three years, versus 1% in the combined-therapy arm [2]. That statistic belongs in any letter to a patient considering stopping Prometrium due to cost.

Prometrium for Specific Clinical Scenarios Covered Differently by UHC

Coverage logic shifts based on the documented indication. Three scenarios come up repeatedly in HealthRX patient intake:

Postmenopausal HRT with intact uterus. This is the strongest coverage case. FDA-approved indication [1], supported by PEPI data [2], endorsed by the Menopause Society [3] and Endocrine Society [4]. PA approval rates are highest here.

Perimenopause with irregular cycles. Coverage is less predictable. UHC reviewers may classify this as off-label if the ICD-10 code submitted is N92.6 (irregular menstruation) rather than N95.0 (postmenopausal bleeding) or N95.1. The prescriber should use the most specific code and include office-note documentation of estrogen dominance symptoms. A 2020 study in Menopause (Vol. 27, Issue 10) demonstrated that micronized progesterone reduced vasomotor symptoms and improved sleep in perimenopausal women, providing a secondary clinical basis for the prescription [10].

Secondary amenorrhea. Also FDA-approved [1], and UHC typically covers this indication with PA, though it may require documentation of serum progesterone levels below 5 ng/mL and exclusion of pregnancy.

Off-label uses (sleep, anxiety, libido). UHC will not approve Prometrium for sleep improvement or anxiolytic benefit under any standard commercial PA criteria. These are not FDA-approved indications. Prescribers documenting only these benefits in PA submissions guarantee denial. The solution is to document the primary indication (endometrial protection or amenorrhea) accurately, not to add off-label rationale.

UHC Medicare Advantage and Prometrium

Medicare Advantage (MA) plans administered by UHC use the CMS national formulary framework. Part D formularies must include at least two drugs in each therapeutic category. Progesterone products appear in formulary category 26 (estrogens/progestins). Generic micronized progesterone is almost universally covered on Part D Tier 1 or Tier 2. Branded Prometrium may not appear on some MA formularies at all.

For MA enrollees denied Prometrium, the escalation path is a Part D Coverage Determination, then a Redetermination (Level 1), then an Independent Review Entity (IRE) review conducted by the CMS-contracted reviewer (currently Maximus Federal Services). Timelines are stricter under Medicare: 72-hour standard coverage determination and 24-hour expedited. The CMS Part D appeals process outlines each step in detail [11].

Low-Income Subsidy (LIS) enrollees pay at most $4.50 for Tier 1 generics in 2025, making branded Prometrium largely a non-issue cost-wise once the generic is confirmed bioequivalent.

When to Ask Your Clinician to Write a Letter of Medical Necessity

A Letter of Medical Necessity (LMN) from a board-certified gynecologist or reproductive endocrinologist carries significantly more weight than one from a general practitioner on UHC PA reviews. The letter should be no longer than one page and must include:

• Patient name, date of birth, and member ID
• ICD-10 diagnosis code(s)
• Duration of treatment recommended (typically 12 months minimum for HRT)
• Clinical rationale citing PEPI [2], the Menopause Society statement [3], and the FDA label [1]
• Statement that the prescriber has considered alternatives and determined micronized progesterone is the appropriate choice
• Prescribing physician's NPI number and direct contact for peer-to-peer review

Request a peer-to-peer review call proactively. UHC's clinical reviewers are board-certified MDs. A five-minute clinician-to-clinician call resolves a substantial proportion of PA denials before they require a formal appeal. Most PA denial letters include instructions for scheduling this call.